Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequence

US11155803B2 · kind B2 · utility

Assignee

• Beam Therapeutics Inc. · US

Inventors

• Nicole Gaudelli · Cambridge, US
• Michael Packer · Cambridge, US
• Ian Slaymaker · Cambridge, US
• Yi Yu · Pittsford, US
• Bernd Zetsche · Cambridge, US
• Jason Michael Gehrke · Cambridge, US
• Natalie PETROSSIAN · Cambridge, US
• Angelica Messana · Cambridge, US
• Yvonne Sarah Aratyn · Cambridge, US
• Francine Gregoire · Lafayette, US
• Genesis LUNG · Cambridge, US
• Shaunna BERKOVITCH · Cambridge, US
• David A. BORN · Cambridge, US
• Seung-Joo Lee · Goyang-si, KR

Key dates

• Filing date: Dec 18, 2020
• Grant date: Oct 26, 2021
• Expiry date: Dec 18, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Y305/04005
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The disclosure provides compositions comprising novel adenosine base editors (e.g., ABE8) that have increased efficiency and methods of using these adenosine deaminase variants for editing a target sequence.